• +1-646-491-9876
    • +91-20-67278686

    Search

    Thyroid Cancer - Pipeline Review, H1 2017

    Thyroid Cancer - Pipeline Review, H1 2017

    • Report Code ID: RW0001709419
    • Category Pharmaceuticals
    • No. of Pages 383
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Thyroid Cancer - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Thyroid Cancer - Pipeline Review, H1 2017, provides an overview of the Thyroid Cancer (Oncology) pipeline landscape.

    Thyroid cancer is a cancer that starts in the thyroid gland. Symptoms include lump that can be felt through the skin on neck, difficulty swallowing, pain in neck and throat and swollen lymph nodes in neck. Predisposing factors include female, high levels of radiation and inherited genetic syndromes. Treatment includes surgery and thyroid hormone therapy.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Thyroid Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Thyroid Cancer (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Thyroid Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Thyroid Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 29, 21, 1, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 5 molecules, respectively.

    Thyroid Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Thyroid Cancer (Oncology) .
    - The pipeline guide reviews pipeline therapeutics for Thyroid Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Thyroid Cancer (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Thyroid Cancer (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Thyroid Cancer (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Thyroid Cancer (Oncology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Thyroid Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 6
    List of Figures 7
    Introduction 8
    Publisher Report Coverage 8
    Thyroid Cancer - Overview 9
    Thyroid Cancer - Therapeutics Development 10
    Pipeline Overview 10
    Pipeline by Companies 11
    Pipeline by Universities/Institutes 15
    Products under Development by Companies 16
    Products under Development by Universities/Institutes 21
    Thyroid Cancer - Therapeutics Assessment 22
    Assessment by Target 22
    Assessment by Mechanism of Action 26
    Assessment by Route of Administration 30
    Assessment by Molecule Type 32
    Thyroid Cancer - Companies Involved in Therapeutics Development 34
    AbbVie Inc 34
    Advenchen Laboratories LLC 34
    AstraZeneca Plc 35
    Bayer AG 35
    BeiGene Ltd 36
    Biovista Inc 36
    Blueprint Medicines Corp 37
    Boehringer Ingelheim GmbH 37
    Celgene Corp 38
    Celldex Therapeutics Inc 38
    Cytori Therapeutics Inc 39
    Daiichi Sankyo Company Ltd 39
    Ecrins Therapeutics SAS 40
    Eisai Co Ltd 40
    Ensol Biosciences Inc 41
    F. Hoffmann-La Roche Ltd 41
    Genelux Corp 42
    Genmab A/S 42
    GlaxoSmithKline Plc 43
    Gradalis Inc 43
    Hutchison MediPharma Ltd 44
    Ignyta Inc 44
    Immune Pharmaceuticals Inc 45
    Immunomedics Inc 45
    Johnson & Johnson 46
    Loxo Oncology Inc 46
    MacroGenics Inc 47
    MaxiVAX SA 47
    Merck & Co Inc 48
    Merck KGaA 48
    Millennium Pharmaceuticals Inc 49
    Nerviano Medical Sciences Srl 49
    Novartis AG 50
    Ono Pharmaceutical Co Ltd 51
    Pfizer Inc 52
    Plexxikon Inc 53
    Rodos BioTarget GmbH 53
    Savoy Pharmaceuticals Inc 54
    Synactix Pharmaceuticals Inc 54
    Tarveda Therapeutics Inc 55
    Vaccinex Inc 55
    Vascular Biogenics Ltd 56
    Thyroid Cancer - Drug Profiles 57
    AL-3818 - Drug Profile 57
    BGB-283 - Drug Profile 60
    BGBA-317 - Drug Profile 63
    BLU-667 - Drug Profile 65
    BVA-501 - Drug Profile 66
    BVA-701 - Drug Profile 67
    CDX-3379 - Drug Profile 68
    ceritinib - Drug Profile 72
    Charis-1000 - Drug Profile 79
    CLM-24 - Drug Profile 80
    CLM-29 - Drug Profile 81
    CLM-3 - Drug Profile 82
    CLM-94 - Drug Profile 83
    crizotinib - Drug Profile 84
    crolibulin - Drug Profile 91
    dabrafenib mesylate - Drug Profile 93
    dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile 98
    docetaxel - Drug Profile 105
    donafenib - Drug Profile 107
    efatutazone - Drug Profile 108
    enoblituzumab - Drug Profile 110
    entrectinib - Drug Profile 113
    ETD-5 - Drug Profile 120
    everolimus - Drug Profile 121
    FAZ-053 - Drug Profile 135
    gemogenovatucel-T - Drug Profile 136
    GI-6207 - Drug Profile 141
    GLONC-2 - Drug Profile 143
    GSK-2256098 - Drug Profile 144
    HMPL-012 - Drug Profile 146
    HuMax-AXL-ADC - Drug Profile 150
    JB-002 - Drug Profile 151
    larotrectinib - Drug Profile 152
    lenvatinib mesylate - Drug Profile 157
    LOXO-292 - Drug Profile 170
    MGD-009 - Drug Profile 171
    MVXONCO-1 - Drug Profile 173
    nintedanib - Drug Profile 175
    NMS-616 - Drug Profile 186
    ofranergene obadenovec - Drug Profile 187
    Oncoprev - Drug Profile 194
    ONO-8430506 - Drug Profile 195
    panobinostat - Drug Profile 196
    pasireotide - Drug Profile 204
    pazopanib hydrochloride - Drug Profile 208
    PDR-001 - Drug Profile 217
    pembrolizumab - Drug Profile 219
    PEN-221 - Drug Profile 267
    pexidartinib - Drug Profile 269
    pimasertib hydrochloride + voxtalisib - Drug Profile 274
    PLX-7486 - Drug Profile 276
    PLX-8394 - Drug Profile 277
    Recombinant Protein for Thyroid Cancer - Drug Profile 278
    regorafenib - Drug Profile 279
    rovalpituzumab tesirine - Drug Profile 291
    RXDX-105 - Drug Profile 293
    sacituzumab - Drug Profile 296
    sapanisertib - Drug Profile 307
    selumetinib sulfate - Drug Profile 310
    Small Molecule 1 to Inhibit RET Receptor Tyrosine Kinase for Medullary Thyroid Cancer - Drug Profile 317
    Small Molecule to Inhibit RET Receptor Tyrosine Kinase for Medullary Thyroid Cancer - Drug Profile 318
    Small Molecules to Inhibit ALK for Oncology - Drug Profile 319
    Small Molecules to Inhibit PAK for Thyroid Cancer - Drug Profile 320
    sunitinib malate - Drug Profile 321
    SYN-001 - Drug Profile 326
    temsirolimus - Drug Profile 327
    TF-2 - Drug Profile 330
    tipifarnib - Drug Profile 333
    TQB-3234 - Drug Profile 337
    trametinib dimethyl sulfoxide - Drug Profile 338
    UB-941 - Drug Profile 343
    utomilumab - Drug Profile 344
    vemurafenib - Drug Profile 347
    VIMO-001 - Drug Profile 355
    VX-15 - Drug Profile 356
    Thyroid Cancer - Dormant Projects 361
    Thyroid Cancer - Discontinued Products 363
    Thyroid Cancer - Product Development Milestones 364
    Featured News & Press Releases 364
    Appendix 377
    Methodology 377
    Coverage 377
    Secondary Research 377
    Primary Research 377
    Expert Panel Validation 377
    Contact Us 377
    Disclaimer 378

    List of Tables

    Number of Products under Development for Thyroid Cancer, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Thyroid Cancer - Pipeline by AbbVie Inc, H1 2017
    Thyroid Cancer - Pipeline by Advenchen Laboratories LLC, H1 2017
    Thyroid Cancer - Pipeline by AstraZeneca Plc, H1 2017
    Thyroid Cancer - Pipeline by Bayer AG, H1 2017
    Thyroid Cancer - Pipeline by BeiGene Ltd, H1 2017
    Thyroid Cancer - Pipeline by Biovista Inc, H1 2017
    Thyroid Cancer - Pipeline by Blueprint Medicines Corp, H1 2017
    Thyroid Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2017
    Thyroid Cancer - Pipeline by Celgene Corp, H1 2017
    Thyroid Cancer - Pipeline by Celldex Therapeutics Inc, H1 2017
    Thyroid Cancer - Pipeline by Cytori Therapeutics Inc, H1 2017
    Thyroid Cancer - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
    Thyroid Cancer - Pipeline by Ecrins Therapeutics SAS, H1 2017
    Thyroid Cancer - Pipeline by Eisai Co Ltd, H1 2017
    Thyroid Cancer - Pipeline by Ensol Biosciences Inc, H1 2017
    Thyroid Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Thyroid Cancer - Pipeline by Genelux Corp, H1 2017
    Thyroid Cancer - Pipeline by Genmab A/S, H1 2017
    Thyroid Cancer - Pipeline by GlaxoSmithKline Plc, H1 2017
    Thyroid Cancer - Pipeline by Gradalis Inc, H1 2017
    Thyroid Cancer - Pipeline by Hutchison MediPharma Ltd, H1 2017
    Thyroid Cancer - Pipeline by Ignyta Inc, H1 2017
    Thyroid Cancer - Pipeline by Immune Pharmaceuticals Inc, H1 2017
    Thyroid Cancer - Pipeline by Immunomedics Inc, H1 2017
    Thyroid Cancer - Pipeline by Johnson & Johnson, H1 2017
    Thyroid Cancer - Pipeline by Loxo Oncology Inc, H1 2017
    Thyroid Cancer - Pipeline by MacroGenics Inc, H1 2017
    Thyroid Cancer - Pipeline by MaxiVAX SA, H1 2017
    Thyroid Cancer - Pipeline by Merck & Co Inc, H1 2017
    Thyroid Cancer - Pipeline by Merck KGaA, H1 2017
    Thyroid Cancer - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
    Thyroid Cancer - Pipeline by Nerviano Medical Sciences Srl, H1 2017
    Thyroid Cancer - Pipeline by Novartis AG, H1 2017
    Thyroid Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
    Thyroid Cancer - Pipeline by Pfizer Inc, H1 2017
    Thyroid Cancer - Pipeline by Plexxikon Inc, H1 2017
    Thyroid Cancer - Pipeline by Rodos BioTarget GmbH, H1 2017
    Thyroid Cancer - Pipeline by Savoy Pharmaceuticals Inc, H1 2017
    Thyroid Cancer - Pipeline by Synactix Pharmaceuticals Inc, H1 2017
    Thyroid Cancer - Pipeline by Tarveda Therapeutics Inc, H1 2017
    Thyroid Cancer - Pipeline by Vaccinex Inc, H1 2017
    Thyroid Cancer - Pipeline by Vascular Biogenics Ltd, H1 2017
    Thyroid Cancer - Dormant Projects, H1 2017
    Thyroid Cancer - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Thyroid Cancer - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Thyroid Cancer, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    AbbVie Inc
    Advenchen Laboratories LLC
    AstraZeneca Plc
    Bayer AG
    BeiGene Ltd
    Biovista Inc
    Blueprint Medicines Corp
    Boehringer Ingelheim GmbH
    Celgene Corp
    Celldex Therapeutics Inc
    Cytori Therapeutics Inc
    Daiichi Sankyo Company Ltd
    Ecrins Therapeutics SAS
    Eisai Co Ltd
    Ensol Biosciences Inc
    F. Hoffmann-La Roche Ltd
    Genelux Corp
    Genmab A/S
    GlaxoSmithKline Plc
    Gradalis Inc
    Hutchison MediPharma Ltd
    Ignyta Inc
    Immune Pharmaceuticals Inc
    Immunomedics Inc
    Johnson & Johnson
    Loxo Oncology Inc
    MacroGenics Inc
    MaxiVAX SA
    Merck & Co Inc
    Merck KGaA
    Millennium Pharmaceuticals Inc
    Nerviano Medical Sciences Srl
    Novartis AG
    Ono Pharmaceutical Co Ltd
    Pfizer Inc
    Plexxikon Inc
    Rodos BioTarget GmbH
    Savoy Pharmaceuticals Inc
    Synactix Pharmaceuticals Inc
    Tarveda Therapeutics Inc
    Vaccinex Inc
    Vascular Biogenics Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//thyroid-cancer-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//thyroid-cancer-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//thyroid-cancer-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments